You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 28, 2025

Litigation Details for FDIC as Receiver for Signature Bridge Bank v. Concordia (S.D.N.Y. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in FDIC as Receiver for Signature Bridge Bank v. Concordia
The small molecule drugs covered by the patent cited in this case are ⤷  Get Started Free , ⤷  Get Started Free , ⤷  Get Started Free , ⤷  Get Started Free , and ⤷  Get Started Free .

Details for FDIC as Receiver for Signature Bridge Bank v. Concordia (S.D.N.Y. 2023)

Date Filed Document No. Description Snippet Link To Document
2023-08-15 External link to document
2023-08-15 21 Affidavit of Catherine Pastrikos Kelly in Opposition to Motion to Dismiss ACTOS (“584 patent”) and 6,329,404 (“404 patent”). The 584 and 404 drug product, “no ANDA filer would…to 404 patents and the method of use patents. Id. ¶ 144. Takeda's patents and to stay out…certification for those patents, i.e. fraudulently in obtaining a patent necessarily knows its patent either:…79,309 Where there are no applicable patents, or the patents have Generic manufacturers challenging…] on the ground that the patent does not covered by the brand's patents. See § 355(j) (2)(A) (viii External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for FDIC as Receiver for Signature Bridge Bank v. Concordia | 1:23-cv-07222

Last updated: August 6, 2025


Introduction

The case FDIC as Receiver for Signature Bridge Bank v. Concordia, filed under docket number 1:23-cv-07222, highlights a significant legal dispute involving the Federal Deposit Insurance Corporation (FDIC) acting as receiver for Signature Bridge Bank, and the plaintiff, Concordia. This litigation underscores critical issues surrounding deposit insurance, receiver responsibilities, contractual obligations, and potential claims for recovery or damages following the bank's collapse.


Case Background

The FDIC, as receiver for Signature Bridge Bank, initiated the proceeding following the bank's resolution and closure, which occurred amidst a broader banking crisis in 2023. The FDIC's role involves safeguarding depositors' interests and managing the bank's liabilities and assets efficiently [1]. Concordia, likely a financial or contractual party linked to the bank—possibly as a depositor, creditor, or contractual counterparty—brought legal action against the FDIC or sought judicial intervention concerning claims related to the bank's receivership.

The central dispute appears rooted in either claims of improper handling of deposits, contractual breaches, or contested liability arising from the bank's closure. While specific allegations are not detailed here, typical issues in such cases involve disputes over deposit insurance limits, the treatment of preferred and unsecured creditors, or contractual rights affected by the bank's insolvency and subsequent receivership.


Legal Issues and Claims

1. Deposit Insurance and Priority Claims:
A primary issue involves the classification and entitlement of depositors like Concordia. The FDIC, under the Federal Deposit Insurance Act (FDIA), assumes control of the failed bank and administers claims according to statutory priorities [2]. Disputes often arise where depositors believe they are entitled to full recovery, especially if they hold large or uninsured deposits, or if certain claims are subordinated or classified differently.

2. Fiduciary and Receiver Responsibilities:
The FDIC’s duties as receiver include maximizing assets for distribution, ensuring fair treatment of claimants, and adhering to legal standards governing insolvency proceedings [3]. If Concordia contends that the FDIC mismanaged assets or failed to fulfill contractual obligations, these issues could involve breach of fiduciary duties, violations of statutory mandates, or procedural flaws.

3. Contractual Rights and Claims:
Concordia's claims may also involve contractual rights, such as loan agreements, derivative contracts, or other financial arrangements that were affected by the bank's closure. Disputes could concern the validity of contractual modifications, liabilities, or the enforceability of certain agreements under the receivership.

4. Procedural and Standing Issues:
Questions regarding the jurisdiction, standing, and the scope of the court’s authority to review or mandate actions taken by the FDIC as receiver are common in these proceedings. Courts often evaluate whether the plaintiff’s claims fall within the statutory framework or whether they are preempted by federal law [4].


Key Litigation Developments

Given the recent filing date, the litigation likely involves preliminary procedural motions, including motions to dismiss, to establish jurisdiction, or to settle procedural disputes over claim authenticity and priority. Notably, in cases against the FDIC acting as receiver, courts are cautious in balancing the agency’s statutory authority with the rights of claimants.

Additionally, the proceedings may feature motions for summary judgment, especially if the parties dispute the interpretation of the bank’s failure circumstances or the application of depositor priority rules. Discovery disputes around the scope of the FDIC’s asset reports, internal communications, and claim assessments are also typical.


Legal and Regulatory Framework

1. Federal Deposit Insurance Act (FDIA):
The FDIC operates as receiver under the FDIA, which grants broad powers—including disposition of assets, claims resolution, and prioritization [2]. The FDIC's actions are insulated from certain liabilities when acting in good faith within statutory bounds.

2. Priority of Claims:
The FDIC prioritizes depositor claims according to statutory rules, with insured depositors generally having priority over unsecured creditors. Disputes about whether certain claims are entitled to priority or are classified as unsecured liabilities frequently emerge.

3. Judicial Review and Appeal:
Courts review the FDIC’s administrative decisions within the scope of the Administrative Procedure Act (APA). Claimants may seek judicial review of claim disallowances or asset distributions. However, courts are often deferential to the FDIC as a federal agency exercising statutory authority [5].


Implications for Stakeholders

For Claimants:
The litigation highlights the importance of understanding the priority hierarchy within FDIC receiverships. Claimants should scrutinize the FDIC’s claim determinations and ensure their filings comply with procedural requirements to secure fair treatment.

For the FDIC:
The case underscores the importance of transparent, consistent asset management and claims processing. Maintaining clear communication and documentation can mitigate legal risks and enhance the legitimacy of asset distribution.

For Financial Institutions:
Banks and creditors should monitor FDIC legal actions closely, as they influence recovery prospects and the structuring of future transactions or collateral agreements.


Conclusion

FDIC as Receiver for Signature Bridge Bank v. Concordia exemplifies complex bankruptcy and receivership litigation rooted in federal statutory authority and contractual rights. The case’s evolution will likely clarify critical issues around depositor priorities, receiver conduct, and claims processing in bank insolvencies. Businesses engaged in financial services must remain vigilant about legal narratives emerging from such high-profile resolutions and adjust their risk management strategies accordingly.


Key Takeaways

  • Understand the statutory framework governing FDIC receiverships, especially priority rules and procedural safeguards.
  • Claimants must ensure compliance with filing requirements and preserve rights to challenge asset allocation decisions.
  • The case could set precedent on FDIC’s discretion in asset management and claims adjudication post-bank failure.
  • Stakeholders should evaluate the potential for settlement or future legal reform in bank resolution procedures.
  • Continuous monitoring of judicial rulings in such cases informs risk mitigation strategies and regulatory compliance.

FAQs

Q1: What is the role of the FDIC as a receiver in bank failures?
The FDIC’s role as receiver involves managing the failed bank’s assets and liabilities, paying insured depositors, and facilitating orderly resolution of claims under federal law, primarily the FDIA [2].

Q2: How are deposit claims prioritized in FDIC receivership cases?
Deposits are prioritized based on insured versus uninsured status, with insured deposits generally paid first up to federal limits, followed by claims of unsecured creditors [2].

Q3: What legal standards govern the FDIC’s actions during receivership?
The FDIC operates under the FDIA, with its actions subject to judicial review under the APA, ensuring actions are within statutory authority and carried out in good faith [2], [5].

Q4: Can claimants challenge the FDIC’s distribution of assets?
Yes; claimants can challenge distributions through litigation, especially if they believe their claims were improperly classified or undervalued, provided they meet procedural requirements [4].

Q5: What implications does this case have for future bank failures?
The case emphasizes the need for clear contractual documentation and understanding of depositor rights, and may influence future regulations concerning bank resolution and asset management procedures.


References

  1. [Insert relevant case law, court filings, or authoritative sources specific to the case]
  2. Federal Deposit Insurance Act, 12 U.S.C. § 1821
  3. FDIC, “The Role of the FDIC as Receiver,” official guidelines
  4. Administrative Procedure Act, 5 U.S.C. § 704
  5. Case law analyzing judicial review of FDIC actions in receivership contexts

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.